clinical relevance of adalimumab serum concentration and anti-adalimumab antibodies in patients...
TRANSCRIPT
-
7/31/2019 CLINICAL RELEVANCE OF ADALIMUMAB SERUM CONCENTRATION AND ANTI-ADALIMUMAB ANTIBODIES IN PATIENTS
1/2
Abstract View
Monday, October 22, 2012
Type: Poster Session
Session title: IBD I
Time: 09.00-17.00
Room: Hall 1
P0296
CLINICAL RELEVANCE OF ADALIMUMAB SERUM CONCENTRATION
AND ANTI-ADALIMUMAB ANTIBODIES IN PATIENTS WITH CROHN
DISEASE DURING LONG-TERM FOLLOW-UP
Giorgia Bodini Poster Presenter
Vincenzo Savarino Co-Author
Lorenzo Gemignani Co-Author
Valentina Fazio Co-Author
Elisa Giambruno Co-Author
Pietro Dulbecco Co-Author
Edoardo Savarino Co-Author
INTRODUCTION/OBJECTIVES:
Trough serum levels of Adalimumab (ADA) and anti-ADA antibodies have been associated to loss ofresponse in patients with inflammatory-related diseases. However, little is known regarding the clinical
influence of these features in patients with Crohns disease (CD) during long-term follow-up.
AIMS & METHODS:To evaluate the course of ADA serum concentration and anti-ADA antibodies formation and their clinicalrelevance during a long-term (2 year) follow-up period of patients with CD. In this prospective study, 22
consecutive infliximab-nave patients (13M/9F) with CD, who achieved remission and in maintenance
treatment with ADA, were included in a follow-up program. Blood samples were drawn at standardizedtime points (i.e. at 6, 12, 18, 24 months and in case of CD relapse) just before injection of ADA. TroughADA serum concentration and anti-ADA antibodies were measured using an enzyme-linked
immunosorbent assays (Matriks biotek). Disease activity was assessed at the same points by means of the
Harvey-Bradshaw Index score (HBI, remission 16) and CRP blood level (normal if
-
7/31/2019 CLINICAL RELEVANCE OF ADALIMUMAB SERUM CONCENTRATION AND ANTI-ADALIMUMAB ANTIBODIES IN PATIENTS
2/2
Patients with CD classified by means of HBI
RemissionMild
DiseaseModerateDisease
SevereDisease
n=10 n=3 n=6 n=3
Parametersp Value(Anova)
HBI score, n 4 (3-4) 6 (5-7) 9 (8-11) 17 (16-17)